None are required, and one paper argues for four. A meta-analysis of 19 randomized trials proposes albumin and lymphocyte count at baseline, then at weeks 12, 24 and 52 [1]. No guideline body has adopted that. It is a reason to know the question exists, not a reason to demand a panel from a telehealth form.
Why the proposal exists
Two numbers describe the same trials and they do not agree. Investigators recorded malnutrition as an adverse event in 0.12% of participants. That is about one person in eight hundred.
The laboratory screening tells a different story. Total lymphocyte counts below 910 per microliter turned up in 2.90% of people on active therapy. On placebo it was 1.77%.
Print both or the comparison lies. The excess on the drug is roughly one percentage point, not the whole 2.90%. Low lymphocytes happen without any drug at all, and a marker is not a diagnosis.
How big the deficit behind it is
Daily energy intake in those trials fell between 24.0% and 39.2%, depending on the drug. The authors model daily deficits reaching 1,200 kcal. That figure is estimated rather than measured.
Tirzepatide at 15 mg lost 1.60 kg of fat-free mass. The authors put that at 2.80% of body weight. You cannot eat a third less and keep the same amount of everything else. The protein side is in how much protein you need, and the tissue side in what a GLP-1 does to muscle.
Values these drugs move without anyone knowing why
A retrospective study checked blood eosinophil counts in 371 adults before and after being prescribed semaglutide [2]. The median fell from 160 to 110 per microliter. The eosinophil percentage fell from 2.20% to 1.60%, and the share below the 150 threshold rose from 44.20% to 65.79%.
No asthma outcome was measured and there was no control group. Eosinophil counts move with season, infection, allergen exposure and steroid use. The clinical meaning of the fall is entirely inferred, as the asthma evidence sets out.
It matters in one specific situation. Suppose an eosinophil count is being used to choose an asthma biologic. A GLP-1 may be moving the number your specialist reads. That is worth mentioning rather than assuming it is irrelevant.
Who gets monitored, and who does not
A meta-analysis of 49 studies covering 5,503,712 people with diabetes asked who receives recommended monitoring [3]. 838,366 of them, 15.2%, had a diagnosed mental disorder. Their odds of receiving any recommended monitoring were 0.81, 95% CI 0.70 to 0.94.
The same direction held on each check. HbA1c testing ran 0.81, retinal screening 0.77, cholesterol measurement 0.83 and foot examination 0.85. The gaps are modest and consistent, and several upper bounds sit close to parity.
That study measures diabetes care quality, not GLP-1 prescribing. A drug whose value depends on follow-up is worth less to a population that receives less of it. What patients report about the variability of clinical support is in what patients said when asked.
What it costs to check
Bloodwork is cheap next to the drug. Most sellers do not include it. So monitoring is a line nobody quotes you, and it is real, avoidable and absent from every price page.
Ask a seller what follow-up is included before the first fill rather than after it. That difference between sellers is larger than the gap in their headline prices. What support is worth is measured in whether a coach changes the result.